TILDRAKIZUMAB, A SELECTIVE IL-23P19 ANTIBODY, IN THE TREATMENT OF CHRONIC PLAQUE PSORIASIS: RESULTS FROM TWO RANDOMIZED, CONTROLLED, PHASE 3 TRIALS

被引：0
|
作者：
Sinclair, R. [1 ]
Reich, K. [2 ,3 ]
Papp, K. [4 ]
Blauvelt, A. [5 ]
Tyring, S. [6 ]
Thaci, D. [7 ]
Cichanowitz, N. [8 ]
Mehta, A. [8 ]
Li, Q. [8 ]
Liu, K. [8 ]
La Rosa, C. [8 ]
Green, S. [8 ]
Kimball, A. [9 ]
机构：
[1] Univ Melbourne, Melbourne, Vic, Australia
[2] Sciderm Res Inst, Hamburg, Germany
[3] Dermatologikum Hamburg, Hamburg, Germany
[4] Prob Med Res, Waterloo, ON, Canada
[5] Oregon Med Res Ctr, Tigard, OR USA
[6] Univ Texas, Austin, TX USA
[7] Univ Lubeck, Lubeck, Germany
[8] Merck & Co Inc, Kenilworth, NJ USA
[9] Harvard Med Sch, Boston, MA USA
来源：
INTERNATIONAL JOURNAL OF DERMATOLOGY | 2017年 / 56卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
0177
引用
收藏
页码：1238 / 1239
页数：2
相关论文
共 50 条
  • [21] TILDRAKIZUMAB EFFICACY OVER TIME BY WEEK 28 RESPONSE LEVELS IN TWO PHASE 3 CLINICAL TRIALS IN PATIENTS WITH CHRONIC PLAQUE PSORIASIS
    Blauvelt, A.
    Sofen, H.
    Papp, K.
    Gooderham, M.
    Zhao, Y.
    Lowry, S.
    Mendelsohn, A.
    Parno, J.
    Li, Q.
    Rosa, C. L.
    Reich, K.
    ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 1602 - 1603
  • [22] Secukinumab Improves Physical Function in Subjects With Plaque Psoriasis and Psoriatic Arthritis: Results from Two Randomized, Phase 3 Trials
    Gottlieb, Alice B.
    Langley, Richard G.
    Philipp, Sandra
    Sigurgeirsson, Bardur
    Blauvelt, Andrew
    Martin, Ruvie
    Papavassilis, Charis
    Mpofu, Shephard
    JOURNAL OF DRUGS IN DERMATOLOGY, 2015, 14 (08) : 821 - 833
  • [23] Selective blockade of IL-23p19 with BI 655066 is associated with significant improvement in QoL outcomes compared with ustekinumab in patients with moderate-to-severe plaque psoriasis
    Papp, Kim A.
    Blauvelt, Andrew
    Bukhalo, Michael
    Gooderham, Melinda
    Lacour, Jean-Philippe
    Menter, Alan
    Philipp, Sandra
    Sofen, Howard
    Tyring, Stephen
    Berner, Beate
    Bennett, Nathan
    Burslem, Kate
    Flack, Mary
    Scholl, Paul
    Padula, Steven
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2016, 74 (05) : AB275 - AB275
  • [24] Efficacy of tildrakizumab in patients with chronic plaque psoriasis: Results from long-term extensions to 2 phase 3 clinical studies
    Papp, K.
    Reich, K.
    Blauvelt, A.
    Thaci, D.
    Kimball, A.
    Sinclair, R.
    Tyring, S.
    Cichanowitz, N.
    Green, S.
    Li, Q.
    La Rosa, C.
    AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2018, 59 : 108 - 108
  • [25] Safety and tolerability of tildrakizumab in patients with chronic plaque psoriasis: Results from long-term extensions of 2 phase 3 studies
    Reich, K.
    Blauvelt, A.
    Thaci, D.
    Papp, K. A.
    Kimball, A.
    Sinclair, R.
    Tyring, S.
    Cichanowitz, N.
    Li, Q.
    Green, S.
    La Rosa, C.
    AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2018, 59 : 110 - 111
  • [26] Effect of Guselkumab a Selective IL-23p19 Inhibitor, on Axial-Related Endpoints in Patients With Active PsA: Results From a Phase 3, Randomized, Double-blind, Placebo-controlled Study Through 2 Years
    Mease, Philip
    Helliwell, Philip
    Gladman, Dafna
    Poddubnyy, Denis
    Baraliakos, Xenofon
    Chakravarty, Soumya
    Kollmeier, Alexa
    Xu, Lillian
    Sheng, Shihong
    Xu, Stephen
    Shawi, May
    van der Heijde, Desiree
    Deodhar, Atul
    JOURNAL OF RHEUMATOLOGY, 2022, 49 (07) : 774 - 774
  • [27] EFFECT OF GUSELKUMAB, A SELECTIVE IL-23P19 INHIBITOR, ON AXIAL-RELATED ENDPOINTS IN PATIENTS WITH ACTIVE PSA: RESULTS FROM A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY THROUGH 2 YEARS
    Mease, P. J.
    Helliwell, P.
    Gladman, D. D.
    Poddubnyy, D.
    Baraliakos, X.
    Chakravarty, S. D.
    Kollmeier, A.
    Xu, X. L.
    Sheng, S.
    Xu, S.
    Shawi, M.
    Van der Heijde, D.
    Deodhar, A.
    ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 832 - 833
  • [28] Certolizumab pegol for the treatment of patients with moderate-to-severe chronic plaque psoriasis: An overview of 3 randomized controlled trials
    Blauvelt, Andrew
    Reich, Kristian
    Drew, Janice
    Peterson, Luke
    Lebwohl, Mark
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2016, 74 (05) : AB239 - AB239
  • [29] Safety and efficacy results from the open label extension of a phase 2 trial of risankizumab, a selective IL-23p19 inhibitor in patients with active psoriatic arthritis
    Papp, Kim A.
    Gooderham, Melinda
    Morita, Akimichi
    Kivitz, Alan J.
    Sinvhal, Ranjeeta
    Topp, Andrew S.
    Heap, Graham A.
    Eldred, Ann
    Mease, Philip J.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2019, 81 (04) : AB271 - AB271
  • [30] Deucravacitinib, a selective, allosteric tyrosine kinase 2 inhibitor, in scalp psoriasis: A subset analysis of two phase 3 randomized trials in plaque psoriasis
    Blauvelt, Andrew
    Rich, Phoebe
    Sofen, Howard
    Strober, Bruce
    Merola, Joseph F.
    Lebwohl, Mark
    Morita, Akimichi
    Szepietowski, Jacek C.
    Lambert, Jo
    Hippeli, Lauren
    Colston, Elizabeth
    Balagula, Eugene
    Banerjee, Subhashis
    Thaci, Diamant
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2024, 90 (04) : 775 - 782
12345